Respiratory syncytial virus
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021. Andrew Kelly | Reuters Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing […]
Read More
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, […]
Read More
Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data suggests […]
Read More
WHO asks China for specifics on respiratory disease outbreaks
Parents acquire their kids to see a health care provider at the pediatric unexpected emergency department of a healthcare facility in Shanghai, China, November 14, 2023. Recently, Shanghai seasonal transform, A influenza and mycoplasma pneumonia large incidence. CFOTO | Potential Publishing | Getty Images The Environment Overall health Firm, or WHO, on Wednesday officially requested […]
Read More
RSV vaccine from GSK shows potential to protect adults 50 to 59
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes thousands of hospitalizations and deaths […]
Read More
CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention’s independent panel of advisors on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, the leading cause of hospitalization […]
Read More
FDA approves Pfizer maternal RSV vaccine for infants
CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. Pfizer’s RSV shot is already approved and available in the U.S. for older adults. It’s now the second treatment […]
Read More
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and belief, Pfizer knowingly […]
Read More
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
Budrul Chukrut | Lightrocket | Getty Images GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company’s new RSV vaccine to start off slower than it did for its blockbuster shingles shot. But she is confident that the new vaccine will drive future sales. “I think the uptake on this we need […]
Read More
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images The Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose of RSV vaccines from Pfizer and GSK after consulting their doctors. Outgoing CDC Director Rochelle Walensky signed off on the recommendation, which an advisory panel […]
Read More